Literature DB >> 23673907

Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.

Arend F L Schinkel1.   

Abstract

BACKGROUND: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a cardiomyopathy characterized by ventricular arrhythmias and an abnormal right ventricle. Implantable cardioverter defibrillator (ICD) therapy may prevent sudden cardiac death in patients with ARVD/C. Currently, an overview of outcomes, appropriate and inappropriate interventions, and complications of ICD therapy in ARVD/C is lacking. METHODS AND
RESULTS: A literature search was performed to identify studies reporting outcome and complications in patients with ARVD/C who underwent ICD implantation. Of 641 articles screened, 24 studies on 18 cohorts were eligible for inclusion. In case of multiple publications on a cohort, the most recent publication was included in the meta-analysis. There were 610 patients (mean age, 40.4 years; 42% women), who had an ICD for primary or secondary prevention of sudden cardiac death. Risk factors for sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricular tachycardia (58%), and ventricular fibrillation (6%). Antiarrhythmic medication consisted mostly of β-blockers (38%), amiodarone (14%), or sotalol (30%). During the 3.8-year follow-up, annualized cardiac mortality rate was 0.9%, annualized noncardiac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%. The annualized appropriate and inappropriate ICD intervention rates were 9.5% and 3.7%, respectively. ICD-related complications consisted of difficult lead placement (18.4%), lead malfunction (9.8%), infection (1.4%), lead displacement (3.3%), and any complication (20.3%).
CONCLUSIONS: Cardiac and noncardiac mortality rates after ICD implantation in patients with ARVD/C are low. Appropriate ICD interventions occur at a rate of 9.5%/y. Inappropriate ICD interventions and complications lead to considerable ICD-related morbidity.

Entities:  

Keywords:  arrhythmogenic right ventricular dysplasia/cardiomyopathy; complication; implantable cardioverter defibrillator; prognosis; sudden cardiac death

Mesh:

Substances:

Year:  2013        PMID: 23673907     DOI: 10.1161/CIRCEP.113.000392

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  24 in total

Review 1.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

2.  Risk stratification in arrhythmogenic right ventricular cardiomyopathy.

Authors:  M Silvano; D Corrado; J Köbe; G Mönnig; C Basso; G Thiene; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-10-11

3.  Risk Stratification in Arrhythmic Right Ventricular Cardiomyopathy Without Implantable Cardioverter-Defibrillators.

Authors:  Francesca Brun; Judith A Groeneweg; Kathleen Gear; Gianfranco Sinagra; Jeroen van der Heijden; Luisa Mestroni; Richard N Hauer; Mark Borgstrom; Frank I Marcus; Trina Hughes
Journal:  JACC Clin Electrophysiol       Date:  2016-06-01

4.  Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death.

Authors:  Kang Yin; Ligang Ding; Yuqiu Li; Wei Hua
Journal:  Clin Cardiol       Date:  2017-01-31       Impact factor: 2.882

Review 5.  Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges.

Authors:  Bruno Pinamonti; Francesca Brun; Luisa Mestroni; Gianfranco Sinagra
Journal:  World J Cardiol       Date:  2014-12-26

6.  Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.

Authors:  Milena Leo; Alexander J Sharp; Andre Briosa E Gala; Michael T B Pope; Timothy R Betts
Journal:  J Interv Card Electrophysiol       Date:  2022-07-14       Impact factor: 1.759

7.  Arrhythmogenic Right Ventricular Cardiomyopathy - Antiarrhythmic Therapy.

Authors:  Simon Ermakov; Melvin Scheinman
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

Review 8.  [Adult advanced life support].

Authors:  Jasmeet Soar; Bernd W Böttiger; Pierre Carli; Keith Couper; Charles D Deakin; Therese Djärv; Carsten Lott; Theresa Olasveengen; Peter Paal; Tommaso Pellis; Gavin D Perkins; Claudio Sandroni; Jerry P Nolan
Journal:  Notf Rett Med       Date:  2021-06-08       Impact factor: 0.826

9.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard N W Hauer; Frank E Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; Na Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Circulation       Date:  2015-07-27       Impact factor: 29.690

Review 10.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard Hauer; Frank Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; N A Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Eur Heart J       Date:  2015-07-27       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.